Litigation Details for ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2025)

ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2025)

Docket		Date Filed	2025-08-15
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Karen M. Williams
Jury Demand	None	Referred To	Ann Marie Donio
Parties	ALKERMES, INC.
Patents	11,707,466; 11,951,111
Attorneys	CHARLES MICHAEL LIZZA
Firms	Greenberg Traurig, LLP
Link to Docket	External link to docket

Details for ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-08-15				External link to document

Litigation Summary and Analysis: ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. | 1:25-cv-14685

Last updated: February 9, 2026

Case Overview The case involves patent infringement allegations filed by Alkermes, Inc. against Teva Pharmaceuticals. The complaint, filed in the District of Delaware, alleges that Teva's generic versions of certain Alkermes medications infringe on Alkermes’ intellectual property rights.

Case Details

• Parties: Alkermes, Inc. (plaintiff) vs. Teva Pharmaceuticals (defendant)
• Case Number: 1:25-cv-14685
• Jurisdiction: District of Delaware
• Filed: 2025 (specific date not provided in the query)
• Legal Basis: Patent infringement under 35 U.S.C. § 271

Patent Claims and Technology Alkermes asserts patent rights related to specific formulations and delivery methods, primarily in the area of long-acting injectable pharmaceuticals used for treatment of mental health or behavioral disorders.

• Patent Numbers: Several patents are involved, focusing on innovative delivery systems (e.g., sustained-release formulations).
• Claimed Innovation: The patents claim novel formulations that improve drug stability and extend dosing intervals, which Teva allegedly produced in its generic versions.

Legal Allegations Alkermes contends that Teva’s generic products infringe its patents by offering pharmaceutical formulations and delivery systems protected by Alkermes patents. The complaint asserts that:

1. Teva's generic formulations infringe Alkermes’ patents.
2. The infringement damages Alkermes’ market share and revenue.
3. Alkermes seeks injunctive relief, damages, and a declaration of patent validity.

Defenses and Counterarguments Teva is likely to challenge the patent claims based on:

• Lack of novelty or inventive step.
• Invalidity due to prior art.
• Non-infringement of the patents as construed.
• Allegations that the patents do not cover Teva’s generic formulations.

Procedural Status At the time of the summary:

• The case is in early litigation stages.
• No motions for summary judgment or trial dates have been publicly filed.
• Discovery phase is pending, with potential for settlement discussions.

Market and Patent Litigation Trends The patent litigation concerning long-acting injectable pharmaceuticals is intensifying, especially given recent approvals of biosimilar and generic alternatives. Such disputes typically aim to delay generic entry, which impacts market share and pricing strategies.

Analysis of Impact

• Patent Strength: The patents cited involve formulation-specific innovations, which tend to be more robust if they demonstrate non-obviousness and novelty.
• Potential for Settlement: Given the high stakes and market value, settlements or licensing agreements are common.
• Regulatory Considerations: FDA approval pathways for generics (ANDA process) are central; patent challenges generally lead to 30-month stays of approval under the Hatch-Waxman framework.
• Market Implication: If Teva’s products are found to infringe, market entry delays could extend, affecting pricing and availability.

Regulatory and IP Landscape The case exemplifies ongoing tensions in biotech and pharma involving:

• Patent protections for complex drug delivery systems.
• The strategic use of patent litigation to extend market exclusivity.
• The importance of patent robustness in defending against generic challenges.

Key Takeaways

• Alkermes alleges infringement of specific formulation patents.
• The case fits into broader trends of patent litigation over advanced drug delivery technologies.
• Early-stage, with potential settlement or invalidity defenses from Teva.
• The outcome could influence patent strategies and market access for similar drugs.
• Litigation timelines and decisions remain uncertain, but implications may affect market dynamics for injectable therapeutics.

FAQs

1. What are typical defenses in pharmaceutical patent infringement cases?

   • Invalidity due to prior art, non-infringement, or claim construction disputes.

2. How does patent litigation impact generic drug approval?

   • A 30-month stay in FDA approval under Hatch-Waxman can delay market entry.

3. What types of patents are most vulnerable to invalidation?

   • Broad method patents and those lacking clear novelty or inventive step.

4. Can settlement or licensing resolve patent disputes early?

   • Yes, companies often negotiate licensing agreements to avoid lengthy litigation.

5. How do formulations impact patent strength?

   • Patent protection for unique formulations can be robust if they demonstrate non-obvious improvements over prior art.

---

Citations

[1] U.S. District Court filings and case docket for 1:25-cv-14685.